BTG-002814 / UCL Cancer Institute, Boston Scientific - LARVOL DELTA

Phase 0 study of vandetanib-eluting radiopaque embolics as a pre-operative embolization treatment in patients with resectable liver malignancies. (PubMed, J Vasc Interv Radiol) - "BTG-002814 has an acceptable safety profile in patients pre-surgery. Presence of vandetanib in tumor specimens up to 32 days post-treatment suggests sustained anticancer activity; low vandetanib plasma levels suggest minimal release into the systemic circulation. Further evaluation of this TACE combination is warranted in dose-finding and efficacy studies."

Journal • Colorectal Cancer • Gastrointestinal Cancer • Hepatocellular Cancer • Oncology • Solid Tumor

Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia. (PubMed, Anticancer Drugs) - "Incubation of tumour spheroids with VERB led to sustained growth inhibition equivalent to the effect of free drug. We conclude that vandetanib has both antiangiogenic and direct anticancer activity against HCC cells even in hypoxic conditions, warranting the further evaluation of VERB as novel anticancer agents."

Journal • Gastrointestinal Cancer • Hepatocellular Cancer • Hepatology • Liver Cancer • Oncology • Solid Tumor • BCL2L11 • EGFR

Vandetanib-eluting Radiopaque Beads: Pharmacokinetics, Safety, and Efficacy in a Rabbit Model of Liver Cancer. (PubMed, Radiology) - "© RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Kim and Van den Abbeele in this issue"

Clinical • Journal • PK/PD data

VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies. (PubMed, JMIR Res Protoc) - P1; "The VEROnA study is studying the feasibility of administering BTG-002814 to optimize the use of this novel technology as liver-directed therapy for patients with primary and secondary liver cancer."

Biomarker • Clinical • Journal

VEROnA: Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies (clinicaltrials.gov) - P1; N=8; Completed; Sponsor: Biocompatibles UK Ltd; Recruiting ➔ Completed; N=12 ➔ 8; Trial completion date: Jan 2019 ➔ Apr 2019; Trial primary completion date: Jan 2019 ➔ Apr 2019

Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date